Pfizer and Eli Lilly announced positive results from a phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis pain. The drug is a humanized monoclonal antibody that is part of an investigational class of non-opioid pain medications known as nerve growth factor (NGF) inhibitors.
The tanezumab 5 mg treatment arm met all three goals at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA compared to those receiving placebo. The tanezumab 2.5 mg treatment arm met two of the three efficacy endpoints compared to placebo.
This is the second readout from the ongoing phase 3 global clinical development program for tanezumab, which includes six studies in approximately 7,000 patients with OA pain, chronic low back pain and cancer pain due to bone metastases. That previous study met all three co-primary efficacy endpoints, demonstrating that among patients with moderate-to-severe OA pain of the knee or hip, both dosing regimens of tanezumab resulted in a statistically significant improvement in pain, physical function and patients’ overall assessment of their OA, compared to placebo.
More than 27 million Americans are living with the progressive joint disease that can cause debilitating physical, emotional and social effects. Approximately 11 million of these patients suffer from moderate-to-severe OA pain.
Read the full release